Wave Life Sciences (NASDAQ:WVE) Announces Earnings Results

Wave Life Sciences (NASDAQ:WVE) issued its quarterly earnings results on Tuesday. The company reported $0.17 EPS for the quarter, topping analysts’ consensus estimates of ($0.18) by $0.35, Zacks reports. Wave Life Sciences had a negative net margin of 66.50% and a negative return on equity of 280.57%.

Wave Life Sciences Stock Up 9.0 %

Shares of WVE opened at $10.96 on Tuesday. The stock has a market capitalization of $1.67 billion, a P/E ratio of -9.84 and a beta of -1.09. Wave Life Sciences has a twelve month low of $4.25 and a twelve month high of $16.74. The firm has a fifty day simple moving average of $11.68 and a two-hundred day simple moving average of $11.15.

Analyst Ratings Changes

A number of research analysts recently commented on WVE shares. StockNews.com raised Wave Life Sciences from a “sell” rating to a “hold” rating in a research note on Thursday, February 27th. HC Wainwright reiterated a “buy” rating and set a $22.00 price objective on shares of Wave Life Sciences in a research report on Wednesday, November 13th. Jefferies Financial Group began coverage on Wave Life Sciences in a research report on Tuesday, February 25th. They issued a “buy” rating and a $26.00 target price for the company. Truist Financial increased their price target on shares of Wave Life Sciences from $17.00 to $36.00 and gave the company a “buy” rating in a research report on Tuesday, November 12th. Finally, B. Riley boosted their price objective on shares of Wave Life Sciences from $19.00 to $22.00 and gave the stock a “buy” rating in a report on Monday, November 4th. Two analysts have rated the stock with a hold rating, eight have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $22.60.

About Wave Life Sciences

Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders.